ArticleNanotechnology, science and applications2025
Development and Evaluation of Trans-Resveratrol-Loaded Transfersomes: Role of Cholesterol in Formulation Design for Dermal Delivery.
Article in Nanotechnology, science and applications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Ultradeformable Vesicles for Wound Healing: Ethosomes, Transferosomes, and Transethosomes in Topical Drug Delivery.Pharmaceutics · 2026Review
- Inhalable Herbal Nano-Liposomes Co-Delivering Astragaloside IV and Polyphyllin VII Reprogram Immunosuppressive Microenvironment To Overcome Anti-PD-1 Resistance in NSCLC.Biological procedures online · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: This study investigated the development and characterization of trans-resveratrol-loaded transfersomes, with and without cholesterol, for potential non-irritating dermal applications. Methods: Transfersomes were prepared using thin-film hydration combined with probe sonication, incorporating hydrogenated lecithin, cholesterol, and Tween Results: All formulations exhibited particle sizes below 150 nm and zeta potentials below -30 mV, indicating favorable characteristics for dermal delivery. Cholesterol incorporation significantly increased particle size and enhanced zeta potential (p<0.05). Formulations containing 3-3.5% w/v hydrogenated lecithin achieved superior entrapment efficiency (>90%) compared to those with lower lecithin content (p<0.05), regardless of cholesterol incorporation. Transfersomes containing cholesterol displayed morphology with well-defined edges compared to cholesterol-free formulations. In vitro release studies revealed distinct release profiles, with cholesterol-free formulations releasing 70-83% of trans-resveratrol over 24 hours, compared to only 0-30% for cholesterol-containing formulations. Strat-M Conclusion: These findings feature the potential of transfersomal systems, particularly cholesterol-free variants, as promising carriers for the effective and safe dermal delivery of trans-resveratrol.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.